Approved peptide drugs are specific medicinal products authorised for use under strictly defined conditions. Regulatory approval should not be interpreted as a general confirmation for every substance designated as a peptide, every formulation containing the same active substance, or every use discussed in scientific publications, clinics, online forums, or commercial offers.
This distinction is particularly important for peptides, because the same active substance can exist in different formulations, delivery systems, strengths, and regulatory contexts. One formulation may be an approved medicinal product, another may still be in the research phase, and a third may be sold as a research material without its corresponding approval as a medicinal product.
The most useful question when checking the regulatory status is therefore very specific:
Is this product, in this formulation and with this route of administration, exactly approved for this specific indication in the given country or regulatory jurisdiction?
The answer requires checking the official register of medicinal products and the current product information. The list of ingredients, the published clinical study, the seller's description, the analysis certificate or a reference to another approved product do not provide the same regulatory confirmation.
This guide explains how to conduct such verification using official sources from the United States, the European Union, and Poland. The products discussed are selected examples to demonstrate the verification process, and not a complete list of approved peptide drugs.
The regulatory sources used in this article were verified on September 25, 2026. The records of medicinal products, indications, product information, and the status of permits may change, therefore, if you need to determine the current status, you should always check the current official sources.
What exactly does regulatory approval cover?
Specific product and specific conditions of its use
The regulatory approval concerns a specific medicinal product that has been submitted for evaluation along with the evidence relating to the intended conditions of its use.
Product documentation usually specifies such elements as the active substance, pharmaceutical form, route of administration, approved indication, appropriate patient population, and relevant limitations, contraindications, and warnings.
Therefore, the approval should be described with sufficient precision so that one approved medicinal product can be distinguished from another formulation containing the same or similar molecule.
The FDA explains that the approval of a drug reflects an assessment of its benefits and risks in a specific application. This does not mean that the drug is free of side effects or that it is suitable for every person and in every clinical situation. [1]
Therefore, the statements:
„This medicine is approved”
should not be extended to:
„This medicine is completely safe.”.
Similarly, it cannot be interpreted as evidence that every possible use of the given active substance has been approved.
From a scientific and editorial point of view, the term „approved peptide” is incomplete if the reader cannot determine which medicinal product and which jurisdiction it refers to.
A more useful description should include the active substance, the product name, the formulation, the route of administration, the approved indication, the official regulatory source, and the date of the information verification.
Clinical publication and regulatory approval are two different sources of information
The publication of a clinical study and the decision to approve the product address different questions.
The scientific article describes a study conducted under specific experimental conditions. It may present results regarding efficacy, pharmacokinetics, safety, or another previously defined endpoint.
The decision of the regulatory authority, however, determines the applicable marketing authorization for a specific medicinal product.
Scientific evidence and regulatory decision-making can be closely related, but they are not equivalent documents.
For example, PIONEER 1 was a randomized study involving 703 participants with type 2 diabetes, in which the oral semaglutide formulation was analyzed, and the main comparison included a 26-week period. [2]
The publication provides evidence regarding a specific intervention, population, and research project.
However, it is not the only current regulatory document concerning all medicinal products containing semaglutide.
The current approved indication should be checked in the current product information published by the competent regulatory authority.
Similarly, a newer clinical study describing an additional potential use does not automatically expand the approved indication. Conversely, an older publication may relate to a formulation, pharmaceutical form, or a population different from the currently available medicinal product.
Scientific evidence and regulatory information should therefore be combined where warranted, while maintaining a separate function for each of these sources.
A useful verification scheme
The structured record of verification makes it easier to track and later update the approval claim.
| Field | What to write down | Why does it matter? |
|---|---|---|
| Jurisdiction | Country or area of application of the permit | Approval is not uniform worldwide |
| Product identity | Trade name and active substance | Similar names can apply to different products |
| Character | Pharmaceutical form, strength and route of administration | Approval does not automatically transfer between formats |
| Indication | Current approved use and appropriate population | The molecule can also be studied in other, unapproved applications. |
| Permission | Official identifier and responsible entity | It combines the statement with a specific entry |
| Status | Current status of the permit and significant changes | The historical approval may differ from the current status |
| Source and date | Official source, version of the document and date of verification | Allows for later updates |
Such a scheme is particularly useful when creating educational and scientific content, because it limits the risk that a general statement about a molecule will be detached from the medicinal product that has actually received approval over time.
However, this is an editorial tool used to verify information.
It does not replace full information about the product and does not allow determining whether a given medication is suitable for a specific person.
Active substance, formulation and indication
The molecule itself does not define the entire medicinal product.
The active substance is a key component of the medicinal product, but it does not define the entire drug on its own.
The formulation and the delivery system are also important.
Tablets, solution for injection and experimental transdermal patches containing the same or related active substance can lead to different pharmacokinetic profiles and be supported by completely different sets of evidence.
A good example is teriparatide.
The EMA documentation regarding Forsteo indicates teriparatide as the active substance of the medicinal product for injection, approved for specific populations with osteoporosis.[3]
Regardless of this, the researchers analyzed teriparatide in an experimental system of delivery using a patch. [4]
The existence of studies on the teriparatide patch does not mean that such an experimental system becomes the approved version of Forsteo.
The active substance may be identical or related, but finished medicinal products and routes of administration do not automatically become interchangeable as a result.
The same applies to research materials.
Identity testing, mass spectrometry, chromatography, or purity measurements can characterize a peptide sample. The results of such analyses may be scientifically valuable, but they do not constitute an authorization for the commercialization of the finished medicinal product.
Indications and populations must be read carefully.
The approved indication specifies the disease, condition or therapeutic purpose for which the medicinal product has been approved.
The content of the indication can also specify a specific population or context of treatment.
Therefore, broad formulations such as:
„approved for metabolism”
or
„approved to support hormones”
they may overlook precisely those information that give the regulatory indication its actual meaning.
Official information about the product should be checked for age groups, disease criteria, treatment circumstances, and other limitations related to the indication.
The details of these should not be replaced by a shorter marketing description just because it is easier to communicate them.
The medicinal product may also have more than one approved indication.
In addition, the indications may be subject to change as a result of subsequent regulatory decisions.
They may be extended, restricted or modified after the product has been initially approved.
Therefore, the old press release regarding the first approval does not have to be the best source for determining the current scope of approval.
Examples of official entries, not a list of therapies
The following examples show how the active substance can be linked to a specific EU entry concerning a medicinal product.
The descriptions are intentionally abbreviated and do not replace the full approved product information.
| Active substance | Example of an official product | Character and general context of the indication |
|---|---|---|
| Teriparatide | Forsteo | Injectable medication for specific populations with osteoporosis |
| Semaglutide | Rybelsus | Oral medication for adults with insufficiently controlled type 2 diabetes |
| Semaglutide | Ozempic | Injectable medication for adults with insufficiently controlled type 2 diabetes |
These examples were verified in the EMA documentation, not on the websites of pharmacies, online retailers, or in retail descriptions.[3][5][6]
They show why the product name and pharmaceutical form remain important even when two medicines contain the same active substance.
Rybelsus and Ozempic contain semaglutide, but the common active ingredient does not mean that their formulations, routes of administration, and all regulatory regulations are interchangeable.
These examples should not be considered a complete catalog of approved peptide drugs or a complete description of all the current listings found in the relevant product documentation.
Use outside of the indicated indications is a separate matter.
Off-label use means the use of an approved medicine outside the conditions specified in its approved product information.
The FDA explains that healthcare workers can in principle prescribe approved medications for non-approved uses if they consider it medically justified, whereas the FDA did not conduct the same safety and efficacy assessment for such use.[1]
This situation should be clearly distinguished from the status of an unapproved research product.
An approved medicinal product used outside the approved indication does not have the same regulatory status as a research vial or an independently manufactured product without an approved medicinal product that corresponds to it.
Regulations regarding the use of off-label may also vary between jurisdictions.
Therefore, educational content should separate three questions: What is the approved indication? What clinical evidence exists for another potential use? What local regulations and professional guidelines allow for prescribing?
Combining these issues can create the misleading impression that evidence of additional use automatically extends regulatory approval.
That is not the case.
How to find official information about a medicinal product?
United States: Start with a list of approved products
In the United States, Drugs@FDA is one of the main official sources for verifying information about product approval.
The FDA describes this database as covering both approved brand-name and generic drugs, as well as many therapeutic biological products, along with access to labeling and other regulatory documents. [7]
Useful search should include both the active substance and the product name.
After finding a potential match, it must be confirmed that the application, pharmaceutical form, route of administration, and sponsor are consistent with the product being evaluated.
The process should not end just because the same ingredient name appears in the search results.
The current label and approval history should then be checked to determine the applicable indication and conditions of use.
In the case of licensed biological products, the next official source is the Purple Book, which contains information about biosimilar and interchangeable products where applicable.[8]
The appropriate base depends on the regulatory category of the specific product.
The very fact that a given substance is scientifically defined as a peptide does not dictate which regulatory framework or pathway applies.
Registration or inclusion in the list does not mean approval
The National Drug Code Directory is often misinterpreted in online discussions regarding the approval of medicines.
The FDA clearly indicates that receiving an NDC number or being included in the NDC Directory does not mean approval by the FDA. [9]
This distinction is important because promotional materials can present the NDC code, the facility registration, or a screenshot of the officially-looking database in a way that suggests regulatory approval.
Such entries may contain useful information, but they do not necessarily answer the question of approval.
Whenever a database is called up, it is worth asking first:
What exactly does this particular database record?
The product database, the clinical trial registry, and the marketing authorization database have different objectives.
Just finding a product or company on the government website does not mean that these categories are equivalent.
This is particularly important when the word „registered” is used in promotional materials in a way that encourages the reader to interpret it as „approved”.
Instead, it is necessary to determine what exact regulatory event took place.
European Union: combine scientific assessment with decision
Under the centralized procedure of the European Union, the EMA conducts the scientific evaluation and makes available information regarding medicinal products, while the European Commission issues the centralized marketing authorization. [10]
There are also national approval paths for products.
The EMA’s website regarding a specific product can provide access to product information, the evaluation history, and changes in regulatory status.
The Union Register contains information from the European Commission regarding the permits for centrally authorised medicinal products. [11]
It is important to distinguish between the individual stages of the regulatory process.
Positive scientific opinion is an important step, but it should not be described automatically as if the final decision of the Commission has already been made.
The EMA guidelines on publication distinguish between scientific opinions, Commission decisions, changes in indications, withdrawal of applications, and subsequent changes in status.[12]
Reliable reporting should preserve these differences.
Similarly, the lack of a product on the EMA websites regarding centrally approved medicines does not mean that the product is not approved anywhere in Europe.
Some products may be approved through national, decentralized, or mutual recognition procedures.
If such a path is possible, the relevant national register should also be checked.
Poland: use the national register of medicinal products
In Poland, the appropriate starting point are the URPL information regarding the Register of Medicinal Products together with the public register of medicinal products [13].
The official register contains information regarding medicinal products authorised through the appropriate channels on the Polish market.
The verification should cover more than just the product name.
The active substance, the pharmaceutical form, and the relevant information regarding the authorization should also be consistent.
In the case of approved clinical data, the Polish Summary of Product Characteristics PL(SPC) is of particular importance.
The patient information leaflet serves a related but different function and is intended for a different group of recipients.
Official interfaces and direct database addresses may change.
If the old registered address stops working, you should find the current registry via the URPL website instead of using the outdated interface indefinitely.
Pharmacy websites, copy of the pages stored by search engines, and trade offers can help in determining the potential product name.
However, they should not constitute the final source of the regulatory approval claim.
The documents should be read as a cohesive set.
Regulatory verification is often stronger when several official documents are analyzed together.
The current status page, current product information, and relevant regulatory history can answer different parts of the question.
The original date of product approval may, for example, be much older than the most recent update of its indication.
Similarly, an early evaluation document may describe a narrower population than a later expansion of the indication.
Therefore, providing only the original approval date may create an incomplete picture of the current regulatory situation.
The practical goal is to create information that can be traced.
The reader should be able to determine which regulatory document was reviewed, which wording confirms the given claim and when the information was current.
If a valid official document cannot be obtained or verified, the uncertainty should be noted instead of filling the gap with a commercial summary.
Approved medicines and research products
The research status does not mean that the product is allowed for sale.
The product may be clinically tested in accordance with the law, without being simultaneously allowed for routine commercial distribution.
The presence of an experimental formulation in a clinical trial does not make it an approved medicinal product.
ClinicalTrials.gov explains that placing a study in the registry does not mean that the U.S. government has approved the safety or scientific validity of every study in the database. [14]
The registration number of the test can be very useful.
It can help identify the protocol, intervention, sponsor, study population, and results.
However, it does not prove that the intervention under investigation is an approved medication.
Registration also does not confirm that the study was successful.
It also does not prove that the product offered commercially is identical to the research material used in the study.
Similarly, the statement:
„This peptide was used in the published study”
it does not constitute a complete regulatory or qualitative assessment.
The research material, manufacturer, formulation, and route of administration may differ significantly from the product offered online.
Prescription and generic products are not synonymous
A generic drug and a prescription drug should not be treated as the same regulatory category.
The FDA distinguishes between approved generic drugs and preparations prepared under the compounding process, and explains that prescription products themselves are not FDA-approved products, although compounding can serve a legitimate medical function under appropriate conditions.[15]
The correct conclusion is therefore not to state that every such product is automatically identical, dangerous, or illegal.
The most important thing is that a prescription drug cannot take over the regulatory status of a brand-name drug or a licensed generic equivalent.
Its legal status and quality requirements must be evaluated in accordance with the principles governing compounding.
Similar caution is necessary for products labeled as „research use only”.
Such labeling does not prove that the product is suitable or approved for use in humans.
The FDA’s information regarding unapproved GLP-1 products discusses, for example, problems associated with unapproved offers and differences between some of the substances sold and the approved formulations.[16]
The product category and its regulatory status must therefore be determined directly, rather than inferred from the familiar name of the ingredient.
The certificate of analysis answers a narrower question
The analysis certificate can contain valuable laboratory information.
Depending on the tests performed, it can provide information regarding the identity, content, purity, or other analytical characteristics of a particular sample.
However, these measurements answer a much narrower question than regulatory approval.
The certificate does not independently assess the entire system of production of the finished product, the route of administration, the clinical balance of benefits and risks, or the approved indication.
Regulatory approval cannot therefore be reproduced by combining a scientific publication on the component with a certificate of purity for the material sourced from another supplier.
Both documents may be authentic.
However, none of them need to confirm the regulatory status of the finished product offered on the market.
If the seller labels a product as an „approved drug”, the appropriate proof is an official entry corresponding to that specific medicinal product.
Status and updates depending on the country
Approval, availability, and reimbursement are different issues
The authorization for marketing is not the same as commercial availability.
The approved medicinal product does not have to be available continuously in every pharmacy or in every country covered by the license.
Similarly, approval does not guarantee reimbursement in a specific health care system.
Approval, commercial availability and reimbursement should therefore be treated as three separate issues.
The EMA guidelines on the marketing status distinguish between notifications related to the placing on the market or the termination of sales from other regulatory events.[17]
This distinction helps to avoid two common mistakes.
Statement:
„This product is not currently sold here”
It does not have to mean:
„This product was never approved here.”.
Similarly:
„This product can be purchased from an online retailer”
does not prove:
„This product is authorized for sale in this jurisdiction.”.
These differences are particularly important when creating international content, because a regulatory entry from one country cannot automatically confirm the current availability, reimbursement, or legality of marketing in another.
The term „retired” requires context.
The word „retired” can refer to several different regulatory events.
The company can withdraw the application before the regulator issues a final decision.
The existing marketing authorization may be later withdrawn, suspended or revoked.
The company may also terminate the sale of the product without an event corresponding to the withdrawal of the license itself.
The EMA publishes information regarding such events in various parts of its documentation. [12]
Therefore, finding the word „retired” should lead to further questions:
What exactly was withdrawn?
Was it a request or an existing permit?
When did this incident happen?
What official reason was given?
Just the mere existence of this word is not enough.
Not every withdrawal means the discovery of a new security problem.
At the same time, it should not be assumed automatically that an old positive regulatory decision still reflects the current status of the product.
Both the event itself and its cause require immediate verification.
Headlines regarding regulatory changes should be interpreted precisely.
Headlines regarding restrictions related to peptides can be particularly misleading if they are interpreted too broadly.
The regulator’s announcement may relate to the ingredients allowed for compounding, a specific medicinal product, enforcement actions against specific sellers, production issues, or a proposed policy change.
This does not necessarily mean that all approved peptide drugs have been withdrawn or banned.
Before updating the article based on the regulatory title, it is necessary to determine the issuing authority, the products or substances covered by the action, the regulatory category, the date of entry into force, and whether the decision is proposed, temporary or final.
The FDA resources regarding compounding are, for example, a suitable starting point when analyzing American issues regarding this category.[15]
However, they do not replace the verification of the entry regarding the approval of a specific medicinal product.
Reliable editorial updates should only change those claims that the regulatory source actually concerns.
A narrow action regarding one regulatory category should not be transformed into a universal statement regarding all products containing peptides.
Frequently asked questions
1. Does the approval cover every use of the given peptide?
No. Approval applies to a specific medicinal product used under defined conditions. The FDA distinguishes approved indications from off-label uses for which the agency has not conducted the same safety and efficacy assessment. [1] Research on another disease or use may provide important scientific information, but the mere publication of the results does not automatically extend product approval. Therefore, a precise statement should indicate a specific drug, jurisdiction, and current indication, rather than presenting a given peptide molecule as generally approved for all proposed uses.
2. Can the research product obtain drug approval?
No. A research material does not become an approved medicinal product just because it contains a substance with the same name as an approved drug. Official documents, such as EMA information regarding Forsteo, refer to the specific finished product and its form. [3] The analytical certificate of the research material supplier, the result regarding purity or the citation of studies on the active substance cannot transfer the regulatory status to another product. Verification must link the specific product to its corresponding approval.
3. Is „peptide therapy” approved by the FDA?
There is no single regulatory approval covering the broad term „peptide therapy”. This term can refer to many different substances, formulations, and proposed uses. The FDA databases contain entries for specific medicinal products, not a single universal approval for all practices referred to as peptide therapy. [7] To verify the claim of approval, one must first determine the specific drug, formulation, route of administration, and approved indication. A general term can be useful descriptively, but it is too broad to itself determine regulatory status.
4. Does the NDC number mean that the product has been approved?
No. The FDA explicitly states that assigning an NDC number or the presence of a product in the NDC Directory does not mean approval by the FDA. [9] An NDC number can provide identification or product entry information, but does not determine whether a product has received appropriate regulatory approval. The claim of approval should be linked to the relevant application or license entry and the current product documentation. An NDC number should be interpreted in accordance with the actual function of the registry, and not as a substitute for a decision on approval.
5. Is the product listed on ClinicalTrials.gov an approved drug?
Not necessarily. ClinicalTrials.gov is a registry of trials, and its presence does not imply government approval of the safety or scientific validity of any registered study. [14] Some studies already involve approved drugs being studied in additional applications; others involve experimental products without marketing approval. A listing in the registry can provide useful information about the protocol and intervention, but the regulatory status of the product must be verified separately in the relevant official drug database.
6. Does the positive opinion from the EMA mean that a final permit has already been issued?
Not in isolation. In the centralized EU procedure, the EMA scientific assessment and the final decision of the European Commission are separate regulatory steps. The EMA’s publication guidelines distinguish between these steps. [12] Therefore, the description should indicate whether it is a positive scientific opinion, a subsequent decision by the Commission, or another regulatory event. Maintaining this distinction prevents presenting an important but incomplete step of the procedure as the final approval for marketing.
7. Does the lack of a result in the EMA mean that the drug is not approved in Poland?
No. Not every drug available in the European regulatory system must be approved through the centralized EMA procedure. National, decentralized, and mutual recognition procedures may also be relevant. [10][13] Therefore, before drawing a conclusion regarding Poland, it is necessary to check the national medicinal product register using the correct product name, active substance, and pharmaceutical form. A lack of results in one database may be due to its scope, differences in nomenclature, or regulatory pathway, rather than a lack of authorization.
8. Are the prescription drug and the approved generic drug the same thing?
No. The FDA distinguishes between approved generic drugs and preparations prepared under the compounding process. Prescription products themselves do not receive product approval by the FDA, although compounding may have legitimate uses under appropriate legal and professional conditions.[15] Therefore, a prescription product should not be presented as an approved generic drug simply because it contains the same active ingredient. Common ingredients, similar packaging, or price differences do not confirm the same regulatory status.
9. Does approval in the United States automatically apply in the EU?
No. Approval in the United States and authorization for marketing in the European Union are decisions taken under different regulatory systems. European centralized approvals and the relevant national pathways should be verified in European and national official sources. [10] An American regulatory entry may provide useful scientific or historical context, but it does not prove that the product is currently approved in the EU. International content should therefore always indicate jurisdiction.
10. Can the oral and injectable products contain the same substance but have different approval details?
Yes. Rybelsus and Ozempic are good examples, as both contain semaglutide, but they are different forms of the medicinal product. [5][6] The common active substance does not mean that the routes of administration, formulations, or all product information are interchangeable. The relevant source remains the current regulatory documentation for the specific product. The same principle applies more broadly to the peptides studied in tablets, injections, patches, and other delivery systems.
11. Does „approved” mean „risk-free”?
No. Regulatory approval reflects an assessment of the benefits and risks under specific conditions of use. It does not mean that adverse reactions cannot occur. The FDA explicitly points out this distinction when discussing approved and non-approved uses. [1] Current product information remains relevant because it includes warnings, contraindications, precautions, and other restrictions. Educational content should therefore accurately describe the approval without transforming it into a general guarantee of safety or individual suitability.
12. Does the withdrawal of the application mean the same thing as the withdrawal of the permit?
No. Withdrawal of the application means that the application for regulatory approval was withdrawn before the completion of the relevant procedure. The withdrawal of a permit, however, concerns a product that already had such a permit. The EMA distinguishes between the withdrawal of the application and subsequent changes to the regulatory status. [12] The word „withdrawal” therefore always requires context. A thorough summary should specify exactly what was withdrawn, when it occurred, and what the official reason was given.
13. Does the published clinical study specify the current approved indication?
No. A clinical study provides scientific evidence but does not replace current approved product information. PIONEER 1 describes, for example, a specific oral semaglutide study in a specific population.[2] It does not independently present all subsequent regulatory decisions regarding all products containing semaglutide. The current indication should be checked in the relevant official product insert. Clinical publications and regulatory documents may complement each other, but each of these sources should answer the question for which it was created.
14. Where should the Polish reader check the status of a peptide drug?
In Poland, the appropriate starting point is the national medicinal product register and the URPL information; in the case of products subject to the centralized EU procedure, the EMA and European Commission documents are also important. [13] Verification should be specific to a particular medicinal product and cover the current CHPL, rather than relying solely on pharmacy descriptions or search results. This allows for the determination of status and approved use based on sources that can be verified. The current commercial availability and reimbursement should still be checked separately.
15. Does the analysis certificate confirm the product’s approval for human use?
No. The analysis certificate and the marketing authorization correspond to completely different questions. Laboratory documentation may contain information regarding the identity, content, purity, or other analytical characteristics of the sample. The official regulatory entry, however, determines the status of a specific medicinal product.[7] Even an authentic high-purity result does not by itself confirm the clinical efficacy, the approved indication, the production status, or the legal authorization of the finished product for human use.
16. Do new restrictions on peptides automatically revoke previous drug approvals?
No. The regulatory notice regarding peptides may refer to compounding, specific ingredients, individual products, enforcement actions, or another narrowly defined issue, rather than all approved peptide drugs. The FDA maintains separate resources regarding compounding and approved medicinal products. [7][15] Before interpreting the new restriction, it is necessary to determine which products or substances it applies to, what their legal category is, which authority issued the decision, when it takes effect, and whether it is final. A narrow regulatory change should not be presented as a blanket ban on peptides or a blanket approval.
17. How to maintain approval information in its current state?
The approval claim should contain enough information to be re-verified later. It is worth recording the exact medicinal product, active substance, formulation, jurisdiction, official regulatory source, the appropriate version of the document and the date of verification. Resources such as the Union Register and the official product history allow tracking regulatory changes over time.[11] Older assessment documents may still contain valuable historical or scientific information, but they should not automatically be treated as a complete description of the current status. A dated and product-specific claim is therefore more reliable than an undated, seemingly static list of „approved peptides”.
Summary
Approved peptide drugs should be understood and verified as specific medicinal products, and not as a broad category of peptide molecules.
The basic regulatory question is not simply whether a given peptide has ever appeared in an approved drug.
The verification should determine the exact product, active substance, pharmaceutical form, route of administration, approved indication, appropriate population, jurisdiction, and the current status of the authorization.
This focused approach on a specific product is important because one active substance can occur in many different contexts.
It can be found in an approved drug, be tested in another delivery system, serve as a research material, or be used in a prescription preparation. These situations do not have the same regulatory status only because the name of the molecule is identical.
The most reliable basis for determining the status of approval are official sources.
In the United States, information regarding a specific product can be found, among other places, in Drugs@FDA and, when applicable, in the Purple Book. [7][8] In the European Union, information from the EMA and documents from the European Commission regarding permits should, where appropriate, be interpreted together. [10][11] In Poland, important national information is provided by the Register of Medicinal Products and the current CHPL. [13]
Scientific publications remain valuable, but they serve a different function.
A randomized clinical trial can provide evidence about a specific intervention and population, without being an actual approved product information at the same time.
Similarly, registration in ClinicalTrials.gov confirms the existence of a research entry, not an authorization to market the product.[14]
The same principle applies to NDC entries and analysis certificates.
The NDC number does not confirm approval by the FDA. [9]
The analysis certificate can contain authentic information regarding the identity or purity, not to mention whether the finished product has been approved as a medicine.
Prescription drugs also require precise nomenclature, because they should not be presented as approved generic drugs just because they contain a known active ingredient.[15]
The regulatory status is also dynamic.
Indications may change.
Authorizations may be extended, suspended, withdrawn, or otherwise modified.
The sale can be completed without the permit itself automatically expiring.
Refunds can vary depending on approval and availability.
Therefore, regulatory claims should always include jurisdiction and the date of verification.
The most reliable conclusion is therefore a narrow and verifiable one:
An approved peptide drug is a specific medicinal product approved for a specific use and under specific conditions in a given regulatory jurisdiction.
Approval of such a product does not automatically include every formulation containing the same molecule, every experimental application, every prescription drug, every research product, or every country.
Disclaimer
This article is for educational, scientific, and informational purposes only regarding regulations. It explains general methods for verifying the approval of medicinal products, indications, formulations, regulatory documentation, and related information about status. It does not constitute medical advice, instructions regarding the prescribing of medications, recommendations for the use of any medicinal product, or individual legal or regulatory opinions.
Regulatory approval does not mean that the drug is suitable for everyone, therefore the article should not be used to make individual treatment decisions. Indications, contraindications, warnings and other clinical information should be checked in the current approved product information and, when applicable, discussed with a suitably qualified healthcare professional.
Regulatory information may also change after the article is published. Permits, indications, product documentation, marketing status, availability, and national requirements may be updated over time. The official sources used in this article were reviewed on September 25, 2026, but you should always check the current regulatory registries when you need up-to-date information.
Scientific publications, clinical trial registrations, NDC entries, analysis certificates, commercial offers, or other supporting documents should not be considered substitutes for the official entry regarding the approval of a specific medicinal product. Regulatory applications should always be verified for a specific product, formulation, route of administration, indication, and jurisdiction.
References
- U.S. Food and Drug Administration. (n.d.). Understanding unapproved use of approved drugs “off label”. Retrieved September 25, 2026, from https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/understanding-unapproved-use-approved-drugs-label
- Aroda, V. R., Rosenstock, J., Terauchi, Y., Altuntas, Y., Lalic, N. M., Morales Villegas, E. C., Jeppesen, O. K., Christiansen, E., Hertz, C. L., Haluzík, M., & PIONEER 1 Investigators. (2019). PIONEER 1: Randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy compared with placebo in patients with type 2 diabetes. Diabetes Care, 42(9), 1724–1732. https://doi.org/10.2337/dc19-0749
- European Medicines Agency. (n.d.). Forsteo. Retrieved September 25, 2026, from https://www.ema.europa.eu/en/medicines/human/EPAR/forsteo
- Cosman, F., Lane, N. E., Bolognese, M. A., Zanchetta, J. R., Garcia-Hernandez, P. A., Sees, K., Matriano, J. A., Gaumer, K., & Daddona, P. E. (2010). Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women. The Journal of Clinical Endocrinology & Metabolism, 95(1), 151–158. https://doi.org/10.1210/jc.2009-0358
- European Medicines Agency. (n.d.). Rybelsus. Retrieved September 25, 2026, from https://www.ema.europa.eu/en/medicines/human/EPAR/rybelsus
- European Medicines Agency. (n.d.). Ozempic. Retrieved September 25, 2026, from https://www.ema.europa.eu/en/medicines/human/EPAR/ozempic
- U.S. Food and Drug Administration. (n.d.). About Drugs@FDA. Retrieved September 25, 2026, from https://www.fda.gov/drugs/drug-approvals-and-databases/about-drugsfda
- U.S. Food and Drug Administration. (n.d.). Purple Book: Database of licensed biological products. Retrieved September 25, 2026, from https://purplebooksearch.fda.gov/
- U.S. Food and Drug Administration. (n.d.). National Drug Code Directory. Retrieved September 25, 2026, from https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory
- European Medicines Agency. (n.d.). Authorisation of medicines. Retrieved September 25, 2026, from https://www.ema.europa.eu/en/about-us/what-we-do/authorisation-medicines
- European Commission. (n.d.). Union Register. Retrieved September 25, 2026, from https://health.ec.europa.eu/medicinal-products/union-register_en
- European Medicines Agency. (n.d.). What EMA publishes and when. Retrieved September 25, 2026, from https://www.ema.europa.eu/en/medicines/what-we-publish-medicines-when
- Office of Registration of Medicinal Products, Medical Devices and Biocidal Products. (n.d.). Register of medicinal products. Retrieved September 25, 2026, from https://www.gov.pl/web/urpl/rejestr-produktow-leczniczych3
- U.S. National Library of Medicine. (n.d.). ClinicalTrials.gov. Retrieved September 25, 2026, from https://clinicaltrials.gov/
- U.S. Food and Drug Administration. (n.d.). Compounding and the FDA: Questions and answers. Retrieved September 25, 2026, from https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
- U.S. Food and Drug Administration. (n.d.). FDA’s concerns with unapproved GLP-1 drugs used for weight loss. Retrieved September 25, 2026, from https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- European Medicines Agency. (n.d.). Notifying a change of marketing status. Retrieved September 25, 2026, from https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/notifying-change-marketing-status